Liminatus Pharma Inc. Stock Soars 10.67% on Rebranding

On July 3, 2025, Liminatus Pharma's stock surged by 10.67% in pre-market trading, reflecting a significant boost in investor confidence.

Liminatus Pharma, a pre-clinical-stage immuno-oncology company, has recently undergone a corporate name change to Liminatus Pharma, Inc. This rebranding effort is part of the company's strategic move to better align with its mission and vision in the immuno-oncology sector.

The company's stock has seen notable volatility, with recent reports indicating a significant decline in its share price. This fluctuation is likely due to market adjustments and investor reactions to the company's strategic initiatives and market positioning.